Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease

被引:543
作者
Schaafsma, JD
Balash, Y
Gurevich, T
Bartels, AL
Hausdorff, JM
Giladi, N
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Neurol,Movement Disorders Unit, IL-64239 Tel Aviv, Israel
[2] Beth Israel Deaconess Med Ctr, Gerontol Div, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
freezing of gait; Parkinson's disease; paroxysmal gait disturbances;
D O I
10.1046/j.1468-1331.2003.00611.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To assess the effect of levodopa on distinct freezing of gait (FOG) subtypes in patients with 'off' FOG. Nineteen patients (12 men, mean age 62.0 +/- 8.4 years) with Parkinson's disease and clinically significant FOG during 'off' states were videotaped whilst walking 130 m during 'off' and 'on' states. Three independent observers characterized the type, duration, and clinical manifestations and quantified FOG by analyzing the videotapes. Their combined mean scores were used for statistical analysis. The intra-class correlation coefficient assessed inter-observer reliability. Wilcoxon and Friedman tests evaluated differences in mean frequencies of FOG characteristics. During 'off' states, FOG was elicited by turns (63%), starts (23%), walking through narrow spaces (12%) and reaching destinations (9%). These respective values were only 14, 4, 2 and 1% during 'on' states (P < 0.011). Moving forward with very small steps and leg trembling in place were the most common manifestations of FOG; total akinesia was rare. Most FOG episodes took < 10 s and tended to be shorter during 'on' states. Levodopa significantly decreased FOG frequency (P < 0.0001) and the number of episodes with akinesia (P < 0.001). Distinction amongst FOG subtypes enables evaluation of distinctive therapeutic response. Levodopa helps in reducing the frequency and duration of 'off'-related FOG.
引用
收藏
页码:391 / 398
页数:8
相关论文
共 28 条
[1]   DOPAMINE AGONIST TREATMENT OF FLUCTUATING PARKINSONISM - D-2 (CONTROLLED-RELEASE MK-458) VS COMBINED D-1 AND D-2 (PERGOLIDE) [J].
AHLSKOG, JE ;
MUENTER, MD ;
BAILEY, PA ;
STEVENS, PM .
ARCHIVES OF NEUROLOGY, 1992, 49 (05) :560-568
[2]   START HESITATION - SIDE-EFFECT OF LONG-TERM LEVODOPA THERAPY [J].
AMBANI, LM ;
VANWOERT, MH .
NEW ENGLAND JOURNAL OF MEDICINE, 1973, 288 (21) :1113-1115
[3]   INFLUENCE OF DYSTONIA ON RESPONSE TO LONG-TERM L-DOPA THERAPY IN PARKINSONS-DISEASE [J].
ANDREWS, CJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1973, 36 (04) :630-636
[4]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[5]   RELATIVE DOPAMINE D1 AND D2 RECEPTOR AFFINITY AND EFFICACY DETERMINE WHETHER DOPAMINE AGONISTS INDUCE HYPERACTIVITY OR ORAL STEREOTYPY IN RATS [J].
ARNT, J ;
BOGESO, KP ;
HYTTEL, J ;
MEIER, E .
PHARMACOLOGY & TOXICOLOGY, 1988, 62 (03) :121-130
[6]   APOMORPHINE FOR MOTOR FLUCTUATIONS AND FREEZING IN PARKINSONS-DISEASE [J].
CORBOY, DL ;
WAGNER, ML ;
SAGE, JI .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (03) :282-288
[7]   Motor fluctuations in Parkinson's disease [J].
Denny, AP ;
Behari, M .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 165 (01) :18-23
[8]  
FAHN S, 1995, ADV NEUROL, V67, P53
[9]  
Fahn S., 1987, RECENT DEV PARKINSON, P153
[10]   Diagnostic criteria for Parkinson disease [J].
Gelb, DJ ;
Oliver, E ;
Gilman, S .
ARCHIVES OF NEUROLOGY, 1999, 56 (01) :33-39